Hypothesis-based investigation of known AD risk variants reveals the genetic underpinnings of neuropathological lesions observed in Alzheimer’s-type dementia
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Besides neurofibrillary tangles and amyloid beta (Aβ) plaques, a wide range of co-morbid neuropathological features can be observed in AD brains. Since AD has a very strong genetic background and displays a wide phenotypic heterogeneity, this study aims at investigating the genetic underpinnings of co-morbid and hallmark neuropathological lesions. This was realized by obtaining the genotypes for 75 AD risk variants from low-coverage whole-genome sequencing data for 325 individuals from the Leuven Brain Collection. Association testing with deeply characterized neuropathological lesions revealed a strong and likely direct effect of rs117618017, a SNP in exon 1 of APH1B, with tau-related pathology. Second, a relation between APOE and granulovacuolar degeneration, a proxy for necroptosis, was also discovered in addition to replication of the well-known association of APOE with AD hallmark neuropathological lesions. Additionally, several nominal associations with AD risk genes were detected for pTDP pathology, α-synuclein lesions and pTau-related pathology. These findings were confirmed in a meta-analysis with three independent cohorts. For example, we replicated a prior association between TPCN1 (rs6489896) and LATE-NC risk. Furthermore, we identified new putative LATE-NC-linked SNPs, including rs7068231, located upstream of ANK3. We found association between BIN1 (rs6733839) and α-synuclein pathology, and replicated a prior association between USP6NL (rs7912495) and Lewy body pathology. Additionally, we also found that UMAD1 (rs6943429) was nominally associated with Lewy body pathology. Overall, these results contribute to a broader general understanding of how AD risk variants discovered in large-scale clinical genome-wide association studies are involved in the pathological mechanisms of AD and indicate the importance of downstream elimination of phenotypic heterogeneity introduced in these studies.
Authors
- Alicja Ronisz (ORCID: https://orcid.org/0000-0002-4310-0445)
- Philip Van Damme (ORCID: https://orcid.org/0000-0002-4010-2357)
- Klara Gawor (ORCID: https://orcid.org/0000-0001-7571-5420)
- Kristel Sleegers (ORCID: https://orcid.org/0000-0002-0283-2332)
- Dietmar Rudolf Thal (ORCID: https://orcid.org/0000-0002-1036-1075)
- Fahri Küçükali (ORCID: https://orcid.org/0000-0002-3835-9639)
- Markus Otto (ORCID: https://orcid.org/0000-0003-4273-4267)
- Rik R. Vandenberghe (ORCID: https://orcid.org/0000-0001-6237-2502)
- Sandra O. Tomé (ORCID: https://orcid.org/0000-0001-5253-0730)
- Christine A. F. Von Arnim (ORCID: https://orcid.org/0000-0002-8614-2223)
- Jasper Van Dongen (ORCID: https://orcid.org/0000-0001-5599-0046)
- Celeste Laureyssen (ORCID: https://orcid.org/0000-0002-7373-2099)
Institutions
- Allen Institute for Brain Science (US)
- University of Antwerp (BE)
- Universitair Ziekenhuis Leuven (BE)
- Universitätsmedizin Göttingen (DE)
- VIB-UAntwerp Center for Molecular Neurology (BE)
- VIB-KU Leuven Center for Brain & Disease Research (BE)
- Martin Luther University Halle-Wittenberg (DE)
- UCLouvain (BE)
- KU Leuven (BE)
Publication Details
- Journal
- Acta Neuropathologica
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1007/s00401-024-02815-w
- Citations
- 4
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Alzheimer's Association
- BrightFocus Foundation
- Onderzoeksraad, KU Leuven